Nektar Therapeutics (NKTR) Cash & Current Investments: 2010-2025
Historic Cash & Current Investments for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to $270.2 million.
- Nektar Therapeutics' Cash & Current Investments rose 10.52% to $270.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $920.0 million, marking a year-over-year decrease of 17.01%. This contributed to the annual value of $255.2 million for FY2024, which is 15.94% down from last year.
- Latest data reveals that Nektar Therapeutics reported Cash & Current Investments of $270.2 million as of Q3 2025, which was up 53.61% from $175.9 million recorded in Q2 2025.
- In the past 5 years, Nektar Therapeutics' Cash & Current Investments registered a high of $1.0 billion during Q1 2021, and its lowest value of $175.9 million during Q2 2025.
- Its 3-year average for Cash & Current Investments is $297.0 million, with a median of $271.2 million in 2024.
- In the last 5 years, Nektar Therapeutics' Cash & Current Investments crashed by 40.68% in 2022 and then climbed by 10.52% in 2025.
- Nektar Therapeutics' Cash & Current Investments (Quarterly) stood at $734.0 million in 2021, then slumped by 31.20% to $505.0 million in 2022, then slumped by 39.88% to $303.6 million in 2023, then dropped by 15.94% to $255.2 million in 2024, then grew by 10.52% to $270.2 million in 2025.
- Its last three reported values are $270.2 million in Q3 2025, $175.9 million for Q2 2025, and $218.6 million during Q1 2025.